Capricor Therapeutics Faces Class Action Over Misleading Deramiocel Statements

Capricor Therapeutics Faces Class Action Lawsuit Over Misleading Statements on Deramiocel

Capricor Therapeutics, Inc. finds itself at the center of a class action lawsuit filed by Rosen Law Firm, a leading global investor rights law firm. The lawsuit pertains to potential misrepresentations related to Capricor's lead cell therapy candidate, deramiocel, which is designed to address cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Investors who purchased Capricor securities between October 9, 2024, and July 10, 2025, are reminded of the crucial lead plaintiff deadline of September 15, 2025. The allegations suggest that the company misled investors about the drug's likelihood of receiving a Biologics License Application (BLA) from the U.S. Food and Drug Administration (FDA).

The lawsuit highlights significant concerns regarding Capricor's transparency about deramiocel's safety and efficacy data from the Phase 2 HOPE-2 trial. Allegedly, the company failed to disclose adverse facts that could have influenced investors' decisions. Misleading investors about the regulatory prospects of deramiocel could have substantial implications not only for Capricor's reputation but also for the broader landscape of treatments for DMD, a condition that affects many families. The repercussions of this lawsuit may extend beyond Capricor to impact investor trust in biotech firms developing therapies for rare diseases, particularly as transparency becomes increasingly vital in the face of regulatory scrutiny.

Rosen Law Firm has positioned itself as a strong advocate for investors, emphasizing the importance of choosing qualified legal counsel in such matters. With a proven track record in securities class actions, the firm claims to have achieved significant settlements, including the largest in a case against a Chinese company. Their experience underscores a commitment to protecting investor rights, having recovered over $438 million for investors in 2019 alone. The firm’s founding partner, Laurence Rosen, is recognized as a prominent figure in the plaintiffs' bar, further asserting the firm's capability to navigate complex securities litigation successfully.

In light of these developments, Capricor Therapeutics faces critical challenges not only in addressing the allegations but also in maintaining investor confidence amid ongoing legal scrutiny. As the deadline for participation in the class action approaches, potential investors and current stakeholders will likely keep a close eye on the outcome of this lawsuit and its implications for the company's future in the rapidly evolving biotech sector.